<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25393363</article-id><article-id pub-id-type="pmc">4647256</article-id><article-id pub-id-type="pii">bjc2014570</article-id><article-id pub-id-type="doi">10.1038/bjc.2014.570</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Comment on: The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer</article-title><alt-title alt-title-type="running">Letters to the Editor</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mesker</surname><given-names>W E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Dekker</surname><given-names>T J A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>de Kruijf</surname><given-names>E M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Engels</surname><given-names>C C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>van Pelt</surname><given-names>G W</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Smit</surname><given-names>V T H B M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tollenaar</surname><given-names>R A E M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Surgery, Leiden University Medical Center (LUMC)</institution>, Leiden, <country>The Netherlands</country></aff><aff id="aff2"><label>2</label><institution>Department of Pathology, Leiden University Medical Center (LUMC)</institution>, Leiden, <country>The Netherlands</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>w.e.mesker@lumc.nl</email></corresp></author-notes><pub-date pub-type="ppub"><day>26</day><month>05</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>13</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>5</month><year>2015</year></pub-date><volume>112</volume><issue>11</issue><fpage>1832</fpage><lpage>1833</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 Cancer Research UK</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Cancer Research UK</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><!--author-paid--><license-p>This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/">http://creativecommons.org/licenses/by-nc-sa/3.0/</ext-link></license-p></license></permissions></article-meta></front><body><p>It has been demonstrated that reactive stromal formation in solid tumours is associated with disease progression and poor outcome. Genes have been identified that are involved in biological processes such as angiogenesis and alterations in the extracellular matrix, including desmoplasia. (<xref ref-type="bibr" rid="bib9">Gao <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib17">Planche <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib3">Berdiel-Acer <italic>et al</italic>, 2014</xref>; <xref ref-type="bibr" rid="bib6">Dakhova <italic>et al</italic>, 2014</xref>; <xref ref-type="bibr" rid="bib8">Duss <italic>et al</italic>, 2014</xref>).</p><p>The presence of stromal cells located in the interior of the tumour, surrounded by small groups or nests of tumour cells, is partly determinative of its (pre) metastatic capacity. Over the last decade, the tumour-stroma ratio (TSR) has gained significant interest in the disease prediction of patients with breast, colon, oesophageal, lung and cervical cancer. The elegance of the parameter is the use of conventional Hematoxylin &#x00026; Eosin-stained slides for histopathological microscopy analysis. The use of a simple cut-off value, proven to be applicable for multiple solid tumour types, distinguishes between stroma-high and stroma-low tumours, of which the stroma-high tumours are independently associated with a relatively worse prognosis. (<xref ref-type="bibr" rid="bib13">Mesker <italic>et al</italic>, 2007</xref>, <xref ref-type="bibr" rid="bib14">2009</xref>; <xref ref-type="bibr" rid="bib4">Courrech Staal <italic>et al</italic>, 2010</xref>; <xref ref-type="bibr" rid="bib20">West <italic>et al</italic>, 2010</xref>; <xref ref-type="bibr" rid="bib2">Beck <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib5">Courrech Staal <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib11">de Kruijf <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib1">Ahn <italic>et al</italic>, 2012</xref>; <xref ref-type="bibr" rid="bib10">Huijbers <italic>et al</italic>, 2012</xref>; <xref ref-type="bibr" rid="bib15">Moorman <italic>et al</italic>, 2012</xref>; <xref ref-type="bibr" rid="bib18">Wang <italic>et al</italic>, 2012</xref>, <xref ref-type="bibr" rid="bib19">2013</xref>; <xref ref-type="bibr" rid="bib7">Dekker <italic>et al</italic>, 2013</xref>; <xref ref-type="bibr" rid="bib12">Liu <italic>et al</italic>, 2014</xref>; <xref ref-type="bibr" rid="bib16">Park <italic>et al</italic>, 2014</xref>).</p><p>The TSR has demonstrated the highest prognostic power when looking at the population of triple-negative breast tumours. For this group of patients, the prognostic hazard ratio (HR) for disease recurrence was reported as high as 4.12 (<italic>P</italic>=0.006) and 3.0 (<italic>P</italic>=0.0034) for patients harbouring stroma-rich tumours. (10,13). Furthermore, within our own data set, oestrogen receptor-positive patients also show a significant relapse-free survival (RFS) difference in the disadvantage for stroma-producing tumours (RFS <italic>P</italic>=0.001, HR 1.8). Similar results were observed in the POP study (<xref ref-type="bibr" rid="bib11">de Kruijf <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib7">Dekker <italic>et al</italic>, 2013</xref>).</p><p>Now, Downey <italic>et al</italic> present the analysis of 118 female breast cancers with stromal formation resulting in a relatively favourable prognosis. These data are in contrast with formerly obtained data on breast and other solid cancers scoring the TSR parameter as described by our group (and subsequently validated by others). (<xref ref-type="bibr" rid="bib13">Mesker <italic>et al</italic>, 2007</xref>, <xref ref-type="bibr" rid="bib14">2009</xref>; <xref ref-type="bibr" rid="bib4">Courrech Staal <italic>et al</italic>, 2010</xref>; <xref ref-type="bibr" rid="bib20">West <italic>et al</italic>, 2010</xref>; <xref ref-type="bibr" rid="bib2">Beck <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib5">Courrech Staal <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib11">de Kruijf <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib1">Ahn <italic>et al</italic>, 2012</xref>; <xref ref-type="bibr" rid="bib10">Huijbers <italic>et al</italic>, 2012</xref>; <xref ref-type="bibr" rid="bib15">Moorman <italic>et al</italic>, 2012</xref>; <xref ref-type="bibr" rid="bib18">Wang <italic>et al</italic>, 2012</xref>, <xref ref-type="bibr" rid="bib19">2013</xref>; <xref ref-type="bibr" rid="bib7">Dekker <italic>et al</italic>, 2013</xref>; <xref ref-type="bibr" rid="bib12">Liu <italic>et al</italic>, 2014</xref>; <xref ref-type="bibr" rid="bib16">Park <italic>et al</italic>, 2014</xref>). In the rest of this letter, we will describe methodological differences between the method used by Downey <italic>et al</italic> and previously published reports, which might underlie the differences in results.</p><p>First, Downey <italic>et al</italic> evaluate only one 9&#x02009;mm<sup>2</sup> area at the tumour's leading or non-leading edge. This area was selected with the emphasis that the advancing &#x02018;front' of a tumour may be more proliferative and the metabolic activity of tumour cells in this area is not compromised by a potential lack of nutrients. This method of TSR scoring of a given tumour underestimates the heterogeneity within the tumour concerning stromal production (<xref ref-type="bibr" rid="bib21">Zhang <italic>et al</italic>, 2014</xref>). It is our personal experience that a solid tumour can be very heterogeneous for desmoplastic characteristics. Estimation of the TSR as indicated by our group entails evaluation of the complete tumour area after which the TSR is determined based on the intratumoural area with the highest degree of stromal formation (<xref ref-type="bibr" rid="bib13">Mesker <italic>et al</italic>, 2007</xref><xref ref-type="bibr" rid="bib14">, 2009</xref>; <xref ref-type="bibr" rid="bib4">Courrech Staal <italic>et al</italic>, 2010</xref>; <xref ref-type="bibr" rid="bib11">de Kruijf <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib5">Courrech Staal <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib1">Ahn <italic>et al</italic>, 2012</xref>; <xref ref-type="bibr" rid="bib10">Huijbers <italic>et al</italic>, 2012</xref>; <xref ref-type="bibr" rid="bib15">Moorman <italic>et al</italic>, 2012</xref>; <xref ref-type="bibr" rid="bib18">Wang <italic>et al</italic>, 2012</xref>, <xref ref-type="bibr" rid="bib19">2013</xref>; <xref ref-type="bibr" rid="bib7">Dekker <italic>et al</italic>, 2013</xref>; <xref ref-type="bibr" rid="bib12">Liu <italic>et al</italic>, 2014</xref>; <xref ref-type="bibr" rid="bib16">Park <italic>et al</italic>, 2014</xref>). For colorectal cancer, it has been shown that the deepest invasive part of the tumour is the most determinative for tumour progression and almost invariably demonstrates the highest stromal formation (if any). For breast cancer this is not applicable, possibly in part because these tumours do not progress through adjacent, consecutive tissue layers as is the case in colorectal tumours (mucosa, submucosa, muscle layers and so on). As such, the area with the highest amount of desmoplasia cannot be predicted and thus warrants evaluation of all available microscopic slides. Also for cervical, non-small lung and oesophageal cancer confirmatory data was observed (<xref ref-type="bibr" rid="bib4">Courrech Staal <italic>et al</italic>, 2010</xref>, <xref ref-type="bibr" rid="bib5">2011</xref>; <xref ref-type="bibr" rid="bib18">Wang <italic>et al</italic>, 2012</xref>, <xref ref-type="bibr" rid="bib19">2013</xref>; <xref ref-type="bibr" rid="bib12">Liu <italic>et al</italic>, 2014</xref>).</p><p>Downey's study also did not indicate whether patients were pre-treated with radio, chemo or endocrine therapy. The studies by <xref ref-type="bibr" rid="bib15">Moorman <italic>et al</italic> (2012)</xref> and <xref ref-type="bibr" rid="bib11">de Kruijf <italic>et al</italic> (2011)</xref> excluded patients with neoadjuvant therapy as therapy influences the tissue arrangement including desmoplasia. Furthermore, no clinical-pathological data with respect to the proportion of stroma was provided, and neither were data for univariate analysis.</p><p><xref ref-type="bibr" rid="bib20">West <italic>et al</italic> (2010)</xref> used an identical approach as Downey for colorectal cancer, for this study an area of the luminal region was selected, resulting in a comparable cut-off points and survival data within stages I&#x02013;III as given for the conventional TSR scoring. For this study no patients with pre-operative chemo or radiotherapy were included.</p><p>In the current setting we do not think that the reported method of Downey <italic>et al</italic> validates the approach of the TSR as it was only based on a subselected tumour area. The previously described TSR by our group is determined on the distribution of the stroma within the complete tumour including areas with heterogeneity and highly aggressive stromal formation. These contrasting reports illustrate the use of stringent criteria for scoring intratumoural stromal formation in order to reliably integrate the TSR into clinical decision-making.</p></body><back><ref-list><ref id="bib1"><mixed-citation publication-type="journal">Ahn S, Cho J, Sung J, Lee JE, Nam SJ, Kim KM, Cho EY (<year>2012</year>) <article-title>The prognostic significance of tumor-associated stroma in invasive breast carcinoma</article-title>. <source>Tumour Biol</source>
<volume>33</volume>(5): <fpage>1573</fpage>&#x02013;1580.<pub-id pub-id-type="pmid">22581521</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal">Beck AH, Sangoi AR, Leung S, Marinelli RJ, Nielsen TO, van de Vijver MJ, West RB, van de Rijn M, Koller D (<year>2011</year>) <article-title>Systematic analysis of breast cancer morphology uncovers stromal features associated with survival</article-title>. <source>Sci Transl Med</source>
<volume>3</volume>(108): <fpage>108ra113</fpage>.</mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal">Berdiel-Acer M, Sanz-Pamplona R, Calon A, Cuadras D, Berenguer A, Sanjuan X, Paules MJ, Salazar R, Moreno V, Batlle E, Villanueva A, Mollev&#x000ed; DG (<year>2014</year>) <article-title>Differences between CAFs and their paired NCF from adjacent colonic mucosa reveal functional heterogeneity of CAFs, providing prognostic information</article-title>. <source>Mol Oncol</source>
<volume>8</volume>(7): <fpage>1290</fpage>&#x02013;1305.<pub-id pub-id-type="pmid">24839936</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal">Courrech Staal EF, Wouters MW, van Sandick JW, Takkenberg MM, Smit VT, Junggeburt JM, Spitzer-Naaykens JM, Karsten T, Hartgrink HH, Mesker WE, Tollenaar RA (<year>2010</year>) <article-title>The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy</article-title>? <source>Eur J Cancer</source>
<volume>46</volume>(4): <fpage>720</fpage>&#x02013;728.<pub-id pub-id-type="pmid">20044247</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal">Courrech Staal EF, Smit VT, van Velthuysen ML, Spitzer-Naaykens JM, Wouters MW, Mesker WE, Tollenaar RA, van Sandick JW (<year>2011</year>) <article-title>Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies</article-title>. <source>Eur J Cancer</source>
<volume>47</volume>(3): <fpage>375</fpage>&#x02013;382.<pub-id pub-id-type="pmid">21036599</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal">Dakhova O, Rowley D, Ittmann M (<year>2014</year>) <article-title>Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression <italic>in vivo</italic></article-title>. <source>Clin Cancer Res</source>
<volume>20</volume>(1): <fpage>100</fpage>&#x02013;109.<pub-id pub-id-type="pmid">24150235</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal">Dekker TJA, van de Velde CJH, van Pelt GW, Kroep JR, Julien J-P, Smit VTHBM, Tollenaar RAEM, Mesker WE (<year>2013</year>) <article-title>Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854)</article-title>. <source>Breast Cancer Res Treat</source>
<volume>139</volume>(2): <fpage>371</fpage>&#x02013;379.<pub-id pub-id-type="pmid">23709090</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal">Duss S, Brinkhaus H, Britschgi A, Cabuy E, Frey DM, Schaefer DJ, Bentires-Alj M (<year>2014</year>) <article-title>Mesenchymal precursor cells maintain the differentiation and proliferation potentials of breast epithelial cells</article-title>. <source>Breast Cancer Res</source>
<volume>16</volume>(3): <fpage>R60</fpage>.<pub-id pub-id-type="pmid">24916766</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal">Gao Q, Wang XY, Qiu SJ, Zhou J, Shi YH, Zhang BH, Fan J (<year>2011</year>) <article-title>Tumor stroma reaction-related gene signature predicts clinical outcome in human hepatocellular carcinoma</article-title>. <source>Cancer Sci</source>
<volume>102</volume>(8): <fpage>1522</fpage>&#x02013;1531.<pub-id pub-id-type="pmid">21564420</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal">Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, Domingo E, Smit VT, Midgley R, Warren BF, Johnstone EC, Kerr DJ, Mesker WE (<year>2012</year>) <article-title>The proportion of intra-tumor stroma as a strong prognosticator for stage II and III colorectal cancer patients, validation in the VICTOR trial</article-title>. <source>Ann Oncol</source>
<volume>24</volume>(1): <fpage>179</fpage>&#x02013;185.<pub-id pub-id-type="pmid">22865778</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal">de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, Kuppen PJ, Tollenaar RA, Mesker WE (<year>2011</year>) <article-title>Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients</article-title>. <source>Breast Cancer Res Treat</source>
<volume>125</volume>(3): <fpage>687</fpage>&#x02013;696.<pub-id pub-id-type="pmid">20361254</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal">Liu J, Liu J, Li J, Chen Y, Guan X, Wu X, Hao C, Sun Y, Wang Y, Wang X (<year>2014</year>) <article-title>Tumor-stroma ratio is an independent predictor for survival in early cervical carcinoma</article-title>. <source>Gynecol Oncol</source>
<volume>132</volume>(1): <fpage>81</fpage>&#x02013;86.<pub-id pub-id-type="pmid">24219981</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal">Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, Tollenaar RA (<year>2007</year>) <article-title>The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage</article-title>. <source>Cell Oncol</source>
<volume>29</volume>(5): <fpage>387</fpage>&#x02013;398.<pub-id pub-id-type="pmid">17726261</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal">Mesker WE, Liefers GJ, Junggeburt JM, van Pelt GW, Alberici P, Kuppen PJ, Miranda NF, van Leeuwen KA, Morreau H, Szuhai K, Tollenaar RA, Tanke HJ (<year>2009</year>) <article-title>Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients</article-title>. <source>Cell Oncol</source>
<volume>31</volume>(3): <fpage>169</fpage>&#x02013;178.<pub-id pub-id-type="pmid">19478385</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal">Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven EA (<year>2012</year>) <article-title>The prognostic value of tumour-stroma ratio in triple-negative breast cancer</article-title>. <source>Eur J Surg Oncol</source>
<volume>38</volume>(4): <fpage>307</fpage>&#x02013;313.<pub-id pub-id-type="pmid">22264965</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal">Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CS (<year>2014</year>) <article-title>The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer</article-title>. <source>Ann Oncol</source>
<volume>25</volume>(3): <fpage>644</fpage>&#x02013;651.<pub-id pub-id-type="pmid">24458470</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal">Planche A, Bacac M, Provero P, Fusco C, Delorenzi M, Stehle JC, Stamenkovic I (<year>2011</year>) <article-title>Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer</article-title>. <source>PLoS One</source>
<volume>6</volume>(5): <fpage>e18640</fpage>.<pub-id pub-id-type="pmid">21611158</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal">Wang K, Ma W, Wang J, Yu L, Zhang X, Wang Z, Tan B, Wang N, Bai B, Yang S, Liu H, Zhu S, Cheng Y (<year>2012</year>) <article-title>Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma</article-title>. <source>J Thorac Oncol</source>
<volume>7</volume>(9): <fpage>1457</fpage>&#x02013;1461.<pub-id pub-id-type="pmid">22843085</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal">Wang Z, Liu H, Zhao R, Zhang H, Liu C, Song Y (<year>2013</year>) <article-title>[Tumor-stroma ratio is an independent prognostic factor of non-small cell lung cancer]</article-title>. <source>Zhongguo Fei Ai Za Zhi</source>
<volume>16</volume>(4): <fpage>191</fpage>&#x02013;196.<pub-id pub-id-type="pmid">23601299</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal">West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W, Treanor D, Quirke P, Grabsch H (<year>2010</year>) <article-title>The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients</article-title>. <source>Br J Cancer</source>
<volume>102</volume>(10): <fpage>1519</fpage>&#x02013;1523.<pub-id pub-id-type="pmid">20407439</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal">Zhang Z, Weaver DL, Munjal K, Evans MF (<year>2014</year>) <article-title>Intratumoral DNA content heterogeneity in breast carcinomas demonstrated by core punch tissue sampling and flow cytometry</article-title>. <source>J Clin Pathol</source>
<volume>67</volume>: <fpage>821</fpage>&#x02013;824.<pub-id pub-id-type="pmid">24942799</pub-id></mixed-citation></ref></ref-list></back></article>